China Approves Fourth COVID-19 Vaccine for Emergency Use

TAIPEI China has approved a new COVID-19 vaccine for emergency use, one that was developed by the head of its Centers for Disease Control, which adds to its arsenal.

Also Read: Explained What we know about China-made vaccines

China’s CDC chief, Gao Fu, led the development of a protein subunit vaccine, approved last week by regulators for emergency use, China’s Academy of Sciences Institute of Microbiology said in a statement on Monday.

This is the fourth vaccine approved for emergency use. China has approved four vaccines developed by three Chinese companies for general use.

The vaccine has been developed by Anhui Zoifei Longcom Biopharmaceutical Company Limited and the Chinese Academy of Sciences. According to the statement, the team finished the Phase 1 and Phase 2 clinical trials in October last year and is currently conducting the final phase of testing in Uzbekistan, Pakistan and Indonesia.

The vaccine was approved for use in Uzbekistan on 1 March.

The protein subunit vaccine is similar to many other vaccines that have been approved globally to train the body to recognize spike proteins that cover the surface of the coronovirus vaccine, although the difference is that it recognizes the body. Lies in the manner of. Protein. Scientists develop a harmless version of the protein in cells and then purify it, before it is assembled into a vaccine and injection.

There is no publicly available information in peer-reviewed scientific journals about clinical trial data showing effectiveness or safety. A spokesperson for the company said that data cannot be shared at this time, but the company is actively providing information to health officials.

China has been slow to vaccinate its population of 1.4 billion people, while four vaccines are approved for general use. According to government officials at a press briefing on Monday in Beijing, the latest number is that it contains 64.98 million doses of vaccines.

China has targeted what it considers important populations to be vaccinated, namely health care workers as well as those working at the border or customs and specific industries the government has chosen. A second group, which has hitherto been absent compared to many other countries, has been the elderly and people with pre-existing conditions.

Vaccines were previously limited to adults only 18–59 years of age, as officials cited a lack of clinical trial data for those who seem to indicate to the government that the limits are now being set aside . “We will immediately conduct mass vaccination of the relevant population,” National Health Commission vice-chairman Lee Bin said on Monday.

China’s state-run Xinhua News Agency reported over the weekend that in some areas of Beijing, local health centers began offering vaccines to people 60 and older.